{"brief_title": "RNA-Loaded Dendritic Cell Cancer Vaccine", "brief_summary": "The purpose of this trial is to examine the safety, feasibility, immunological response, and clinical antitumor activity of administering a dendritic cell vaccine to patients with metastatic renal cell carcinoma.", "condition": ["Renal Cell Carcinoma"], "intervention_type": ["Biological"], "intervention_name": ["MB-002"], "description": ["Dendritic Cell Immunotherapy"], "arm_group_label": ["MB-002-003"], "criteria": "Inclusion Criteria: - Have a new diagnosis of metastatic renal cell carcinoma; - Must be at least 18 years or older; - Have a scheduled unilateral nephrectomy; - ECOG of 0 or 1; - Free of brain metastases by CT or MRI; - Normal renal function in contralateral kidney; - Male or non-pregnant/non-lactating female on appropriate birth control methods while on study; - Clinically acceptable screening results. - No immunosuppressive therapy not limited to corticosteroids (including topical steroids or steroid containing inhalers), azathioprine cyclosporine two months prior to study entry; - No active autoimmune disease", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Renal cancer", "mesh_term": ["Carcinoma", "Carcinoma, Renal Cell"], "id": "NCT00087984"}